Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab

Recent developments in immune checkpoint inhibitors (ICIs) have provided new treatment strategies for advanced cancer. However, ICIs lead to an imbalance between T cell–mediated inflammatory responses and immune tolerance in the myocardium. Here we report the first case that implicates the contribut...

Descripción completa

Detalles Bibliográficos
Autores principales: Oishi, Hideo, Morimoto, Ryota, Shimoyama, Yoshie, Kuroda, Kei, Urata, Toru, Kondo, Toru, Okumura, Takahiro, Bando, Yasuko K., Akiyama, Masashi, Murohara, Toyoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Mini-Focus Issue: Cardiomyopathies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299122/
https://www.ncbi.nlm.nih.gov/pubmed/34317084
http://dx.doi.org/10.1016/j.jaccas.2020.07.028
_version_ 1783726202819706880
author Oishi, Hideo
Morimoto, Ryota
Shimoyama, Yoshie
Kuroda, Kei
Urata, Toru
Kondo, Toru
Okumura, Takahiro
Bando, Yasuko K.
Akiyama, Masashi
Murohara, Toyoaki
author_facet Oishi, Hideo
Morimoto, Ryota
Shimoyama, Yoshie
Kuroda, Kei
Urata, Toru
Kondo, Toru
Okumura, Takahiro
Bando, Yasuko K.
Akiyama, Masashi
Murohara, Toyoaki
author_sort Oishi, Hideo
collection PubMed
description Recent developments in immune checkpoint inhibitors (ICIs) have provided new treatment strategies for advanced cancer. However, ICIs lead to an imbalance between T cell–mediated inflammatory responses and immune tolerance in the myocardium. Here we report the first case that implicates the contribution of ICI-induced vasculitis to myocardial injury. (Level of Difficulty: Intermediate.)
format Online
Article
Text
id pubmed-8299122
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-82991222021-07-26 Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab Oishi, Hideo Morimoto, Ryota Shimoyama, Yoshie Kuroda, Kei Urata, Toru Kondo, Toru Okumura, Takahiro Bando, Yasuko K. Akiyama, Masashi Murohara, Toyoaki JACC Case Rep Mini-Focus Issue: Cardiomyopathies Recent developments in immune checkpoint inhibitors (ICIs) have provided new treatment strategies for advanced cancer. However, ICIs lead to an imbalance between T cell–mediated inflammatory responses and immune tolerance in the myocardium. Here we report the first case that implicates the contribution of ICI-induced vasculitis to myocardial injury. (Level of Difficulty: Intermediate.) Elsevier 2020-09-23 /pmc/articles/PMC8299122/ /pubmed/34317084 http://dx.doi.org/10.1016/j.jaccas.2020.07.028 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Mini-Focus Issue: Cardiomyopathies
Oishi, Hideo
Morimoto, Ryota
Shimoyama, Yoshie
Kuroda, Kei
Urata, Toru
Kondo, Toru
Okumura, Takahiro
Bando, Yasuko K.
Akiyama, Masashi
Murohara, Toyoaki
Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
title Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
title_full Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
title_fullStr Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
title_full_unstemmed Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
title_short Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
title_sort myocardial vasculitis associated with the immune checkpoint inhibitor pembrolizumab
topic Mini-Focus Issue: Cardiomyopathies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299122/
https://www.ncbi.nlm.nih.gov/pubmed/34317084
http://dx.doi.org/10.1016/j.jaccas.2020.07.028
work_keys_str_mv AT oishihideo myocardialvasculitisassociatedwiththeimmunecheckpointinhibitorpembrolizumab
AT morimotoryota myocardialvasculitisassociatedwiththeimmunecheckpointinhibitorpembrolizumab
AT shimoyamayoshie myocardialvasculitisassociatedwiththeimmunecheckpointinhibitorpembrolizumab
AT kurodakei myocardialvasculitisassociatedwiththeimmunecheckpointinhibitorpembrolizumab
AT uratatoru myocardialvasculitisassociatedwiththeimmunecheckpointinhibitorpembrolizumab
AT kondotoru myocardialvasculitisassociatedwiththeimmunecheckpointinhibitorpembrolizumab
AT okumuratakahiro myocardialvasculitisassociatedwiththeimmunecheckpointinhibitorpembrolizumab
AT bandoyasukok myocardialvasculitisassociatedwiththeimmunecheckpointinhibitorpembrolizumab
AT akiyamamasashi myocardialvasculitisassociatedwiththeimmunecheckpointinhibitorpembrolizumab
AT muroharatoyoaki myocardialvasculitisassociatedwiththeimmunecheckpointinhibitorpembrolizumab

Ejemplares similares